应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
JNJ 强生
盘后交易 04-25 18:22:18 EDT
146.82
-1.71
-1.15%
盘后
146.70
-0.12
-0.08%
18:13 EDT
最高
149.58
最低
146.33
成交量
763.61万
今开
149.37
昨收
148.53
日振幅
2.19%
总市值
3,538亿
流通市值
3,531亿
总股本
24.10亿
成交额
11.23亿
换手率
0.32%
流通股本
24.05亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
CartaBio完成数千万元天使轮融资,创始人曾任职于美国多家MNC药企
地产k线 · 04-25 23:22
CartaBio完成数千万元天使轮融资,创始人曾任职于美国多家MNC药企
强生下跌1.21%,报146.74美元/股
金融界 · 04-25 22:10
强生下跌1.21%,报146.74美元/股
强生(JNJ.US)&传奇生物CAR-T疗法再获欧盟批准
智通财经 · 04-23 13:51
强生(JNJ.US)&传奇生物CAR-T疗法再获欧盟批准
媒体-J&J公司和Kenvue公司被要求向婴儿爽身粉使用者家属支付4500万美元 - 彭博新闻社
Reuters · 04-21
媒体-J&J公司和Kenvue公司被要求向婴儿爽身粉使用者家属支付4500万美元 - 彭博新闻社
J&J公司在佛罗里达州妇女声称其婴儿爽身粉致癌一案中胜诉
Reuters · 04-19
J&J公司在佛罗里达州妇女声称其婴儿爽身粉致癌一案中胜诉
手术机器人需求强劲,医疗设备制造商直觉公司业绩超出预期
Reuters · 04-19
手术机器人需求强劲,医疗设备制造商直觉公司业绩超出预期
大摩:维持Johnson & Johnson(JNJ.US)评级
智通财经 · 04-18
大摩:维持Johnson & Johnson(JNJ.US)评级
加拿大皇家银行:维持Johnson & Johnson(JNJ.US)评级,由优于大市调整至优于大市
智通财经 · 04-18
加拿大皇家银行:维持Johnson & Johnson(JNJ.US)评级,由优于大市调整至优于大市
BUZZ-街景:J&J 的药品和医疗技术组合将推动销售额增长至 2025 年
Reuters · 04-17
BUZZ-街景:J&J 的药品和医疗技术组合将推动销售额增长至 2025 年
BUZZ-FDA批准Stelara生物仿制药,Teva和Alvotech股价上涨
Reuters · 04-17
BUZZ-FDA批准Stelara生物仿制药,Teva和Alvotech股价上涨
强生2023财年实现净利润133.26亿美元,同比减少25.72%
自选股智能写手 · 04-17
强生2023财年实现净利润133.26亿美元,同比减少25.72%
BUZZ-J&J 医疗技术部门销售额未达预期,医疗器械制造商业绩下滑
Reuters · 04-16
BUZZ-J&J 医疗技术部门销售额未达预期,医疗器械制造商业绩下滑
美股异动|强生跌1.3% 第一季度销售额略低于预期 缩窄EPS指引
新浪财经 · 04-16
美股异动|强生跌1.3% 第一季度销售额略低于预期 缩窄EPS指引
强生公司公布截至 3 月的季度业绩 - 收益摘要
Reuters · 04-16
强生公司公布截至 3 月的季度业绩 - 收益摘要
BUZZ-传奇生物技术公司因与 J&J 合作的血液癌症疗法第一季度销售额下滑而下滑
Reuters · 04-16
BUZZ-传奇生物技术公司因与 J&J 合作的血液癌症疗法第一季度销售额下滑而下滑
强生Q1每股收益超预期,上调全年销售额指引
智通财经网 · 04-16
强生Q1每股收益超预期,上调全年销售额指引
强生(JNJ.US)Q1每股收益超预期 上调全年销售额指引
智通财经 · 04-16
强生(JNJ.US)Q1每股收益超预期 上调全年销售额指引
更新版 1-尼日利亚监管机构:没有召回 J&J 止咳糖浆导致儿童死亡的记录
Reuters · 04-16
更新版 1-尼日利亚监管机构:没有召回 J&J 止咳糖浆导致儿童死亡的记录
尼日利亚药品监管机构:没有儿童死于召回的 J&J 止咳糖浆的记录
Reuters · 04-16
尼日利亚药品监管机构:没有儿童死于召回的 J&J 止咳糖浆的记录
强生一季度销售额213.8亿美元,净利润53.54亿美元
老虎资讯综合 · 04-16
强生一季度销售额213.8亿美元,净利润53.54亿美元
公司概况
公司名称:
强生
所属市场:
NYSE
上市日期:
--
主营业务:
强生公司于1887年在新泽西州成立。强生公司及其子公司在全球拥有大约152,700名员工,从事医疗保健领域的广泛产品的研发,生产和销售。强生公司是一家控股公司,在全球几乎所有国家/地区都有260多家运营公司开展业务。公司的主要重点是与人类健康和福祉相关的产品。强生执行委员会是主要的管理团队,负责公司的战略运营和资源分配。委员会负责监督和协调公司三个业务部门的活动:消费者,制药和医疗设备。
发行价格:
--
{"stockData":{"symbol":"JNJ","market":"US","secType":"STK","nameCN":"强生","latestPrice":146.82,"timestamp":1714075200000,"preClose":148.53,"halted":0,"volume":7636090,"hourTrading":{"tag":"盘后","latestPrice":146.7,"preClose":146.82,"latestTime":"18:13 EDT","volume":434384,"amount":63775985.21808,"timestamp":1714083210442},"delay":0,"floatShares":2405019635,"shares":2409783054,"eps":16.117043,"marketStatus":"盘后交易","marketStatusCode":4,"change":-1.71,"latestTime":"04-25 18:22:18 EDT","open":149.37,"high":149.58,"low":146.33,"amount":1122581056.3737,"amplitude":0.021881,"askPrice":147.59,"askSize":1000,"bidPrice":146.3,"bidSize":3,"shortable":3,"etf":0,"ttmEps":16.117043,"exchange":"NYSE","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1714089600000},"adr":0,"listingDate":-797371200000,"adjPreClose":148.53,"adrRate":0,"dividendRate":0.032421,"preHourTrading":{"tag":"盘前","latestPrice":149,"preClose":148.53,"latestTime":"09:29 EDT","volume":68935,"amount":10240275.63755,"timestamp":1714051770067},"postHourTrading":{"tag":"盘后","latestPrice":146.7,"preClose":146.82,"latestTime":"18:13 EDT","volume":434384,"amount":63775985.21808,"timestamp":1714083210442},"volumeRatio":0.769397},"requestUrl":"/m/hq/s/JNJ/wiki","defaultTab":"wiki","newsList":[{"id":"2430811233","title":"CartaBio完成数千万元天使轮融资,创始人曾任职于美国多家MNC药企","url":"https://stock-news.laohu8.com/highlight/detail?id=2430811233","media":"地产k线","top":-1,"share":"https://www.laohu8.com/m/news/2430811233?lang=zh_cn&edition=full","pubTime":"2024-04-25 23:22","pubTimestamp":1714058558,"startTime":"0","endTime":"0","summary":"瑞财经 刘治颖近日,CartaBio宣布完成数千万元天使轮融资,本轮投资人包括旦恩资本、CohoDeeptech以及产业资本等。据悉,CartaBio成立于2024年,是一家专注于活细胞荧光成像技术研发的公司。公司创始人RobertYang博士曾任职于美国多家顶级MNC药企,深耕计算生物领域超过13年,曾任强生数据科学及生物标志物部门全球负责人,并管理一支35人的全球研发团队,拥有扎实的研发创新能力及丰富的管理经验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404252324028b538ede&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404252324028b538ede&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430811592","title":"强生下跌1.21%,报146.74美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430811592","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430811592?lang=zh_cn&edition=full","pubTime":"2024-04-25 22:10","pubTimestamp":1714054227,"startTime":"0","endTime":"0","summary":"4月25日,强生(JNJ)盘中下跌1.21%,截至22:10,报146.74美元/股,成交1.63亿美元。财务数据显示,截至2024年03月31日,强生收入总额213.83亿美元,同比增长2.34%;归母净利润53.54亿美元,同比增长7973.53%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/25221040414798.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429158464","title":"强生(JNJ.US)&传奇生物CAR-T疗法再获欧盟批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2429158464","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429158464?lang=zh_cn&edition=full","pubTime":"2024-04-23 13:51","pubTimestamp":1713851483,"startTime":"0","endTime":"0","summary":"西达基奥仑赛是一种靶向B细胞成熟抗原的CAR-T疗法。2017年12月,强生旗下强生创新制药与传奇生物签订了全球独家许可和合作协议,以开发和商业化西达基奥仑赛。2022年2月,西达基奥仑赛获得美国FDA批准上市,5月获得EC授予的附条件上市许可,用于治疗复发或难治性多发性骨髓瘤成人患者,这些患者至少接受过3种前期疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042313561587a4794c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042313561587a4794c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429887674","title":"媒体-J&J公司和Kenvue公司被要求向婴儿爽身粉使用者家属支付4500万美元 - 彭博新闻社","url":"https://stock-news.laohu8.com/highlight/detail?id=2429887674","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2429887674?lang=zh_cn&edition=full","pubTime":"2024-04-21 05:07","pubTimestamp":1713647227,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 4月20日 - -- 来源链接: -- 注:路透社未核实此报道,不保证其准确性","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428528539","title":"J&J公司在佛罗里达州妇女声称其婴儿爽身粉致癌一案中胜诉","url":"https://stock-news.laohu8.com/highlight/detail?id=2428528539","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2428528539?lang=zh_cn&edition=full","pubTime":"2024-04-19 05:20","pubTimestamp":1713475212,"startTime":"0","endTime":"0","summary":"Matthey 一家声称,数十年来,强生公司一直知道其开采的用于婴儿爽身粉的滑石粉可能受到致癌石棉纤维的污染。据起诉书称,J&J 公司隐瞒了滑石粉产品与癌症风险增加有关的科学证据。相反,据 J&J 称,科学证据根本不支持 Matthey 家族关于其滑石粉产品致癌的说法。J&J公司的破产策略使滑石粉诉讼从2021年暂停到2023年,但在最新的破产案件被驳回后,审判已经恢复。滑石粉案件的审判记录喜忧参半,主要的原告胜诉包括 2021 年判给 22 名卵巢癌妇女 21 亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428024542","title":"手术机器人需求强劲,医疗设备制造商直觉公司业绩超出预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2428024542","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2428024542?lang=zh_cn&edition=full","pubTime":"2024-04-19 04:44","pubTimestamp":1713473045,"startTime":"0","endTime":"0","summary":"自去年11月以来,投资者对医疗设备制造商业绩的预期一直在提高,因为人们,尤其是老年人,选择了在大流行病期间推迟的医疗程序。直觉公司生产名为达芬奇的手术机器人,截至 3 月 31 日的季度调整后每股收益为 1.50 美元。券商Evercore ISI随后表示,强生公司手术设备销售额的下降很可能反映了市场份额被直觉公司抢走。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428599650","title":"大摩:维持Johnson & Johnson(JNJ.US)评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2428599650","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428599650?lang=zh_cn&edition=full","pubTime":"2024-04-18 20:54","pubTimestamp":1713444856,"startTime":"0","endTime":"0","summary":"大摩:维持Johnson & Johnson(JNJ.US)评级,由持股观望调整至持股观望评级,目标价由168.00美元调整至167.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041821072087908619&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041821072087908619&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428863145","title":"加拿大皇家银行:维持Johnson & Johnson(JNJ.US)评级,由优于大市调整至优于大市","url":"https://stock-news.laohu8.com/highlight/detail?id=2428863145","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428863145?lang=zh_cn&edition=full","pubTime":"2024-04-18 10:03","pubTimestamp":1713405827,"startTime":"0","endTime":"0","summary":"加拿大皇家银行:维持Johnson & Johnson(JNJ.US)评级,由优于大市调整至优于大市评级,目标价由181.00美元调整至175.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404181017048b328ca6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404181017048b328ca6&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428311391","title":"BUZZ-街景:J&J 的药品和医疗技术组合将推动销售额增长至 2025 年","url":"https://stock-news.laohu8.com/highlight/detail?id=2428311391","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2428311391?lang=zh_cn&edition=full","pubTime":"2024-04-17 19:30","pubTimestamp":1713353456,"startTime":"0","endTime":"0","summary":"对滑石粉诉讼的担忧,carvykti** 摩根大通 认为,JNJ 的基础业务定位准确,能够凭借创新药物和医疗技术组合实现 5%以上的持续利润增长。** RBC Capital Markets 认为,尽管 Stelara 的 LOE 存在问题,但 JNJ 现有的产品组合、新产品的推出以及管线的能见度都增强了该公司到 2025 年实现 570 亿美元目标销售额的信心。** BofA Global Research 称,尽管 J&J 2025 年的制药目标可能实现,但投资者仍应在年内静观其变,以进一步明确增长前景。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428386046","title":"BUZZ-FDA批准Stelara生物仿制药,Teva和Alvotech股价上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2428386046","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2428386046?lang=zh_cn&edition=full","pubTime":"2024-04-17 06:05","pubTimestamp":1713305108,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 4月16日 - ** 在美国上市的梯瓦制药 股价在延时交易中上涨~1.5%,至13.28美元** 美国 FDA 批准 (link) Teva 与合作伙伴 Alvotech 的 Selarsdi 注射剂,这是强生公司 Stelara 的生物仿制药,用于治疗银屑病和银屑病关节炎。** ALVO 股价盘后上涨 ~1.7%,报 12.95 美元 ** 在与 JNJ 达成和解协议后,两家公司预计将于 2025 年 2 月 21 日或之后在美国上市 Selarsdi** 截至上一交易日收盘,TEVA上涨25.4%,ALVO上涨10.9%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428870761","title":"强生2023财年实现净利润133.26亿美元,同比减少25.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428870761","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428870761?lang=zh_cn&edition=full","pubTime":"2024-04-17 01:03","pubTimestamp":1713286985,"startTime":"0","endTime":"0","summary":"12月31日,强生公布财报,公告显示公司2023财年净利润为133.26亿美元,同比减少25.72%;其中营业收入为851.52亿美元,同比减少10.38%,每股基本收益为5.59美元。从资产负债表来看,强生总负债987.84亿美元,其中短期债务34.51亿美元,资产负债比为0.01,流动比率为1.16。机构评级:截至2023年12月31日,当前有19家机构对强生目标价做出预测,其中目标均价为176.33美元,其中最低目标价为160.00美元,最高目标价为215.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041701030887851d29&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041701030887851d29&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427871310","title":"BUZZ-J&J 医疗技术部门销售额未达预期,医疗器械制造商业绩下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2427871310","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2427871310?lang=zh_cn&edition=full","pubTime":"2024-04-16 23:25","pubTimestamp":1713281142,"startTime":"0","endTime":"0","summary":" 4月16日 - ** 强生 医疗设备部门公布第一季度 ,销售额为78.2亿美元,低于华尔街预期的78.8亿美元,LSEG数据显示,医疗设备制造商股价下跌1%至3%。** 史赛克 下跌1%,Zimmer Biomet 下跌1.2%,美敦力 下跌1.4%,安捷伦 下跌2.4%,拜登迪金森 下跌0.9%,博士伦 下跌1.7%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2427737878","title":"美股异动|强生跌1.3% 第一季度销售额略低于预期 缩窄EPS指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2427737878","media":"新浪财经","top":-1,"share":"https://www.laohu8.com/m/news/2427737878?lang=zh_cn&edition=full","pubTime":"2024-04-16 22:02","pubTimestamp":1713276135,"startTime":"0","endTime":"0","summary":"强生(JNJ.US)跌1.3%,报145.66美元。消息面上,强生第一季度销售额为213.8亿美元,同比增长2.3%,略低于市场预期的213.9亿美元;调整后的每股收益为2.71美元,好于市场预期的2.65美元。公司预期2024年调整后的每股收益将在10.57至10.72美元之间,之前预测为10.55至10.75美元。\n\n\n股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"us","thumbnail":"http://n.sinaimg.cn/spider20240416/615/w350h265/20240416/5ce3-33ba1e33c70e834b03d599fac67487cc.jpg","type":0,"news_type":0,"thumbnails":["http://n.sinaimg.cn/spider20240416/615/w350h265/20240416/5ce3-33ba1e33c70e834b03d599fac67487cc.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-16/doc-inarzyns9344192.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2427308827","title":"强生公司公布截至 3 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2427308827","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2427308827?lang=zh_cn&edition=full","pubTime":"2024-04-16 21:31","pubTimestamp":1713274270,"startTime":"0","endTime":"0","summary":" * 强生公司 公布的截至 3 月份的季度调整后每股收益为 2.71 美元,高于去年同期的每股收益 2.68 美元。16 位分析师对该季度的平均预期为每股收益 2.64 美元。华尔街预期为每股收益 2.56 美元至 2.74 美元。* 营业收入为 213.8 亿美元,同比下降 13.6%;分析师预期为 214.0 亿美元。* 强生公布的本季度每股收益为 2.20 美元。* 强生股价本季度下跌了 6.7%,今年迄今为止下跌了 5.8%。华尔街对强生公司 12 个月目标价的中位数为 175.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2427725822","title":"BUZZ-传奇生物技术公司因与 J&J 合作的血液癌症疗法第一季度销售额下滑而下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2427725822","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2427725822?lang=zh_cn&edition=full","pubTime":"2024-04-16 21:26","pubTimestamp":1713274004,"startTime":"0","endTime":"0","summary":" 4月16日 - ** 细胞疗法开发商传奇生物科技 股价盘前下跌约9%,至47美元 ** 强生公司 报告称, ,联想合作的癌症细胞疗法Carvykti的第一季度销售额低于预期。** Carvykti 最近获准用于病情较轻的一种血癌患者,其第一季度销售额为 1.57 亿美元。** Carvykti 是 10 种产品之一,J&J 预计其最高销售额将超过 50 亿美元 ** 截至上一交易日收盘,LEGN股价累计下跌约14","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2427822638","title":"强生Q1每股收益超预期,上调全年销售额指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2427822638","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2427822638?lang=zh_cn&edition=full","pubTime":"2024-04-16 21:21","pubTimestamp":1713273702,"startTime":"0","endTime":"0","summary":"财报显示,强生Q1销售额为213.8亿美元,同比增长2.3%,基本符合市场预期的213.9亿美元;调整后的净利润为65.8亿美元,同比增长3.8%;调整后的每股收益为2.71美元,好于市场预期的2.65美元。强生也一直在投资医疗设备。此次收购将进一步扩大强生在心血管领域的医疗器械产品布局。展望未来,强生预计,2024年全年销售额为887亿美元至891亿美元,高于此前预期的882亿至890亿美元,市场预期为884亿美元;预计调整后的每股收益为10.57-10.72美元,此前预期为10.55-10.75美元。","market":"sh","thumbnail":"https://static.tigerbbs.com/8fdf7a7d924886123a73d608af50c43b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/8fdf7a7d924886123a73d608af50c43b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1103567.html","is_publish_highlight":true,"gpt_icon":1},{"id":"2427827981","title":"强生(JNJ.US)Q1每股收益超预期 上调全年销售额指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2427827981","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2427827981?lang=zh_cn&edition=full","pubTime":"2024-04-16 21:14","pubTimestamp":1713273267,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,周二美股盘前,强生公布了其2024年第一季度财务业绩。财报显示,强生Q1销售额为213.8亿美元,同比增长2.3%,基本符合市场预期的213.9亿美元;调整后的净利润为65.8亿美元,同比增长3.8%;调整后的每股收益为2.71美元,好于市场预期的2.65美元。此次收购将进一步扩大强生在心血管领域的医疗器械产品布局。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041621173987845ce3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041621173987845ce3&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427182172","title":"更新版 1-尼日利亚监管机构:没有召回 J&J 止咳糖浆导致儿童死亡的记录","url":"https://stock-news.laohu8.com/highlight/detail?id=2427182172","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2427182172?lang=zh_cn&edition=full","pubTime":"2024-04-16 20:55","pubTimestamp":1713272120,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) (增加了第 2-3 段的背景和细节) 路透社阿布贾4月16日 - 尼日利亚药品监管机构的一位高级官员周二表示,该监管机构没有记录显示有儿童死于强生 生产的一批已被召回的止咳糖浆。尼日利亚国家食品药品监督管理署(NAFDAC) 上周 宣布 (link) ,在实验室检测发现二甘醇含量过高,因此召回一批强生儿童止咳糖浆。NAFDAC药物警戒总监Fraden Bitrus告诉路透社,自2022年以来,由于冈比亚和喀麦隆的儿童死亡事件,监管机构一直在对止咳糖浆进行检测。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2427821688","title":"尼日利亚药品监管机构:没有儿童死于召回的 J&J 止咳糖浆的记录","url":"https://stock-news.laohu8.com/highlight/detail?id=2427821688","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2427821688?lang=zh_cn&edition=full","pubTime":"2024-04-16 20:45","pubTimestamp":1713271555,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 路透社阿布贾4月16日 - 尼日利亚药品监管机构的一位负责人周二表示,监管机构没有记录显示强生公司 生产的一批止咳糖浆被召回后导致儿童死亡。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"1161526625","title":"强生一季度销售额213.8亿美元,净利润53.54亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1161526625","media":"老虎资讯综合","top":-1,"share":"https://www.laohu8.com/m/news/1161526625?lang=zh_cn&edition=full","pubTime":"2024-04-16 18:36","pubTimestamp":1713263766,"startTime":"0","endTime":"0","summary":"第一季度调整后每股收益2.71美元,市场预期2.65美元。","market":"us","thumbnail":"https://static.tigerbbs.com/467642b25d4068394e30bb7339c42aa0","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/467642b25d4068394e30bb7339c42aa0"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.jnj.com","stockEarnings":[{"period":"1week","weight":0.026},{"period":"1month","weight":-0.0431},{"period":"3month","weight":-0.0691},{"period":"6month","weight":0.0201},{"period":"1year","weight":-0.1008},{"period":"ytd","weight":-0.0524}],"compareEarnings":[{"period":"1week","weight":0.0097},{"period":"1month","weight":-0.0276},{"period":"3month","weight":0.0356},{"period":"6month","weight":0.2307},{"period":"1year","weight":0.2446},{"period":"ytd","weight":0.0633}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"强生公司于1887年在新泽西州成立。强生公司及其子公司在全球拥有大约152,700名员工,从事医疗保健领域的广泛产品的研发,生产和销售。强生公司是一家控股公司,在全球几乎所有国家/地区都有260多家运营公司开展业务。公司的主要重点是与人类健康和福祉相关的产品。强生执行委员会是主要的管理团队,负责公司的战略运营和资源分配。委员会负责监督和协调公司三个业务部门的活动:消费者,制药和医疗设备。","yearOnYearQuotes":[{"month":1,"riseRate":0.522727,"avgChangeRate":0.000425},{"month":2,"riseRate":0.5,"avgChangeRate":-0.005666},{"month":3,"riseRate":0.590909,"avgChangeRate":0.016904},{"month":4,"riseRate":0.644444,"avgChangeRate":0.034931},{"month":5,"riseRate":0.477273,"avgChangeRate":-0.027248},{"month":6,"riseRate":0.522727,"avgChangeRate":0.006309},{"month":7,"riseRate":0.590909,"avgChangeRate":0.010998},{"month":8,"riseRate":0.5,"avgChangeRate":0.002512},{"month":9,"riseRate":0.5,"avgChangeRate":0.003139},{"month":10,"riseRate":0.704545,"avgChangeRate":0.022035},{"month":11,"riseRate":0.613636,"avgChangeRate":0.017008},{"month":12,"riseRate":0.659091,"avgChangeRate":0.014337}],"exchange":"NYSE","name":"强生","nameEN":"Johnson & Johnson"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"强生(JNJ)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供强生(JNJ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"强生,JNJ,强生股票,强生股票老虎,强生股票老虎国际,强生行情,强生股票行情,强生股价,强生股市,强生股票价格,强生股票交易,强生股票购买,强生股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"强生(JNJ)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供强生(JNJ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}